Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Abstract A58: KRAS mutations: Variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

2014; American Association for Cancer Research; Volume: 12; Issue: 12_Supplement Linguagem: Inglês

10.1158/1557-3125.rasonc14-a58

1557-3125

Veronica Aran, Fernando Meton de Alencar Câmara Vieira, Ana Paula Victorino, Jonas Hauben Salem, Ilana Zalcberg-Renault, Martín Bonamino, Mariano Zalis, Carlos Gil Ferreira,

Lung Cancer Treatments and Mutations

Abstract Personalised medicine is an evolving field that seeks to target cancer therapies based on unique genetic characteristics of the tumour and/or the patient. One of the most significant advances towards personalised care in the field of oncology was the establishment of KRAS gene mutation as a validated biomarker predicting efficacy in epidermal growth factor receptor (EGFR) targeted therapies in the treatment of metastatic colorectal cancer (mCRC). KRAS mutations are frequently found in CRC indicating the importance of its genotyping in the study of the molecular mechanisms behind this disease. Although major advances have occurred over the past decade, there are still important gaps in our understanding of CRC carcinogenesis, particularly whether sex-linked factors play any role. Therefore, in this study the profile of KRAS mutations in the Brazilian population was analysed by conducting direct sequencing of KRAS codons 12 and 13 belonging to 8,234 metastatic CRC patient samples from different Brazilian regions. The median age was 59 years and the overall percentage of wild-type and mutated KRAS was 66.4% and 33.6%, respectively. Interestingly, a significant difference in the percentage of mutated KRAS patients was observed between male and female (32.5% versus 34.8%, p=0.03). However, there were no differences in the distribution of any specific KRAS mutation according to gender. This is one of the largest cohorts of KRAS genotyping in CRC patients indicating a higher incidence of KRAS mutations in females compared to males. Citation Format: Veronica Aran, Fernando M. Vieira, Ana Paula Victorino, Jonas H. Salem, Ilana Zalcberg-Renault, Martin H. Bonamino, Mariano Zalis, Carlos Gil Ferreira. KRAS mutations: Variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr A58. doi: 10.1158/1557-3125.RASONC14-A58